Shanna Miranti, MPAS, PA-C

 How Dermatology PAs Can Master Rapid Diagnostic Recognition

Shanna Miranti, PA-C, a physician assistant at Riverchase Dermatology, took the stage at the 

 in Colorado to deliver a Kodachromes lecture centered on one of the most practiced yet least formally taught skills in 

: reading a rash or lesion quickly and getting it right.

“The goal of any Kodachromes lecture is to try to improve a provider's diagnostic accuracy, speed, and acuity," Miranti said. “We want dermatology PAs to be just as good as the derm residents at visually diagnosing something quickly and accurately."

A Framework for Narrowing the Differential

Miranti described using the Fitzpatrick skin atlas algorithm as a mental organizing structure, guiding clinicians to first determine whether they are looking at a solitary lesion or multiple lesions and, if multiple, whether the distribution is localized or generalized. She argued that the initial categorization alone meaningfully narrows the differential before a provider ever reaches for a dermoscope.

The approach reflects a broader philosophy: pattern recognition is a trainable skill, not an innate talent. Research supports that even 30 minutes a day spent reviewing image-based diagnostic exercises can help clinicians build their own internal visual algorithm, according to Miranti.

Pediatric dermatology emerged as a focal point of the session. Miranti noted that providers who rarely see children in practice can be caught off guard by presentations unique to pediatric skin, including a greater prevalence of infectious causes and reactions that do not manifest the same way in adults. The workforce picture makes this gap more consequential: as of July 2024, only 371 board-certified pediatric dermatologists practiced across the entire United States, with 8 states having none at all.

"It really is up to dermatology APPs to pick up the slack [and]… help those very overworked, very overwhelmed pediatric dermatologists,” Miranti said. “We can be an extension of their care.”

Even clinicians who do not see pediatric patients in their own practice benefit from familiarity with pediatric dermatoses since patients with children will often bring questions about their kids to whoever is available, Miranti added.

Balancing Speed with Diagnostic Discipline

Miranti said that visual acuity guides a provider toward the most likely diagnosis, but the differential should remain provisional until confirmed. Dermoscopy and biopsy remain essential tools for honing a differential and arriving at the most accurate diagnosis and, therefore, the right treatment.

The session also generated substantial discussion around conditions with overlapping presentations. Macular amyloidosis drew questions from attendees about how to distinguish it from notalgia paresthetica, 2 entities that share enough surface similarity to trip up less experienced clinicians. For Miranti, the answer was familiar: pattern recognition deepens with repetition, and once a provider has biopsied a condition multiple times and seen it resolve, the visual memory becomes durable.

"When we see it, we know it; we don't even need to biopsy it anymore," she said. "But this is definitely a skill that any provider can learn."

Miranti offered a measured read on artificial intelligence in dermatology. AI platforms are improving at pattern recognition, and dermatology APPs are paying attention. But the technology cannot yet perform dermoscopy, obtain tissue, or initiate treatment. The more immediate concern she raised was not professional displacement but patient misinformation: people arriving at appointments having already diagnosed themselves using AI image search tools, sometimes incorrectly.

"Hopefully they seek out medical help," Miranti said, "and hopefully there is a very astute dermatology PA or nurse practitioner who can help them."

Editor's note: Reported disclosures for Miranti include Incyte Corporation, Dermavant Sciences, Ortho Dermatologics, Verrica Pharmaceuticals, Galderma Laboratories, SUN PHARMACEUTICAL INDUSTRIES, ParaPRO, and more.

Miranti S. Kodachromes: A Visual Journey Through Dermatologic Diagnosis. Session presented at SDPA Summer 2026; June 10–14.

Lee S, Aigbekaen I, Huang J. Geographic Maldistribution of Pediatric Dermatologists in Relation to Pediatric and Family Medicine Residency Programs. 

Videos

At SDPA 2026, Shanna Miranti, PA-C, outlined how dermatology PAs can sharpen diagnostic speed and accuracy through structured visual practice and algorithm-based thinking.

How Dermatology PAs Can Master Rapid Diagnostic Recognition

Managing Pediatric AD With New Topicals

Panelists discuss how new nonsteroidal treatments are transforming the management of pediatric atopic dermatitis (AD) by combining efficacy, safety, and convenience. Simplified regimens encourage better adherence, while gentle formulations support long-term use without irritation or systemic risks.

They emphasize the role of caregiver education—teaching families how to maintain treatment routines and address flares early helps sustain progress. Consistent communication builds trust and improves outcomes, allowing children to live more comfortably and confidently.

Panelists conclude that integrating innovative therapies with supportive care strategies creates a balanced, sustainable approach to managing chronic AD in young patients.




Panelists discuss how new nonsteroidal therapies improve adherence, comfort, and long-term skin health for children with AD.

Ruxolitinib Efficacy and Safety in Pediatric AD

Panelists discuss how newer studies exploring JAK-targeting creams for children with mild to moderate atopic dermatitis (AD) demonstrate encouraging efficacy and sustained response. Many patients experience visible improvement and reduced itch within weeks, with benefits maintained over time.

Panelists also highlight favorable safety profiles, noting that adverse effects are generally mild and limited to the treatment area. These outcomes support expanding nonsteroidal options for children, reducing reliance on corticosteroids for long-term control.

Caregiver feedback reinforces the value of well-tolerated, easy-to-apply therapies that integrate smoothly into daily life, enhancing consistency and confidence.



Panelists discuss how JAK-targeting topical therapies offer effective, well-tolerated solutions for children with mild to moderate AD.

Roflumilast Efficacy and Safety in Pediatric AD

Panelists discuss how recent research has evaluated nonsteroidal topical agents for mild to moderate pediatric atopic dermatitis (AD), showing encouraging results for safety, tolerability, and durability. These findings suggest that effective inflammation control can be achieved with minimal irritation or adverse effects.

They highlight the importance of meaningful measures—such as itch reduction, body surface area improvement, and quality-of-life scores—to guide treatment decisions. These patient-centered outcomes help clinicians tailor therapies to what matters most for families.

Panelists emphasize that as research continues, these data-driven insights will refine treatment approaches and support individualized care for every child.

Panelists discuss how evidence from clinical studies supports the safety and effectiveness of new nonsteroidal treatments for children with AD.

Shanna Miranti, MPAS, PA-C

Articles